{"name":"Hangzhou Sumgen Biotech Co., Ltd.","slug":"hangzhou-sumgen-biotech-co-ltd","ticker":"","exchange":"","domain":"hangzhousumgen.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SG1827","genericName":"SG1827","slug":"sg1827","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SG301","genericName":"SG301","slug":"sg301","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"SG1827","genericName":"SG1827","slug":"sg1827","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SG301","genericName":"SG301","slug":"sg301","phase":"phase_3","mechanism":"SG301 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"prnewswire.com","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"prnewswire.com","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - prnewswire.com","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOenZwWnVZZTJIRTVqNlF5cEJwZHhzWGFMay1aYVVsN2l3b3BEWHpkYU5VN1BJSlhYa2kzMlAwZ09EMFJEZXdTNXJzajVYLVdZWUJrRHAza3ZreGY1UlRNaWUwYUl0cEQ2NFJPMEJJelFoWWYxMWRZOVE3UmQydDRQRk5oVTloaEdhUEZCVXJPZmpGSEVPcWZ6ZFBueTdOdmlpSDVJQmVhZkVkWVByNEZETGxPc1lBNXFKanpRWllUaHVWZTJmRVR5aDlVelpvYXk4LWpPT2hmZFVOOWV4Z1Q0cEVZUDBINEk2QVpsWDFCOERfQmxMWnQwQlloT3NoVGVsTnA2NXQ5VHVjRDhBdjctTUw1bmFFT0xwclJSQ2QwdE1CUFMtV3JsbW1PTQ?oc=5","date":"2024-10-22","type":"trial","source":"prnewswire.com","summary":"JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the Domain - prnewswire.com","headline":"JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Co","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOWWtWVEJmZjJicldndWR5TDVVMFF5bkhhQTNoWjRIekVMdDF3T3FzYmV4MkJhaDZoS29qRUlzTU1UbVZhUXRoX212bzI1aEpRcVNWekRIVlFaOHRDX1hzY1poQ21YUmlQQmlzZzNialFMWmJGMlIyLXNNVVgzMTBfa3ozT1lOQnFHSEVOM19ielFWWDVGYlVxLQ?oc=5","date":"2024-10-18","type":"trial","source":"Oncology Pipeline","summary":"LaNova enters oncology’s hottest licensing territory | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"LaNova enters oncology’s hottest licensing territory | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNd0xfQ0dxa0VhdGNvZ1pjd21Td2ZuSS0zbjNqMWtDU1dmNU5CLV8xUkFsdVR5TjJFQTBrdVdudjg0WGN4QUJrdmNJYnZ2TEVTVnFFTXFxQU5STWdKc21XbkNMM0JuWXpqUTNFVklKcUpzTk4yV21DS2lPR1Yxd0dERWUtc1ExOTRfcF84MWI0MFNiLS1ZclZKM0FBS3dUbndRWU4wLUhHM2xndFRFcHVKak52cVUxWS1MM0NlUUQ5NkF2UEJKY1ZtMTRZbkkxenFYVGstVUw3TnNvUHlaQkNpMlAxeXZwdl8wdkFvQVBmbEV2ZXk5YlYzSkV6dkJ2bm9rb2lGWmVJcEw2czgyZEJscFB2cUdrdlRXcllUbnZVVVNxSUx0M0x6YlA0Z0ZNZ29VTVpXbE9Tdw?oc=5","date":"2024-01-08","type":"trial","source":"GlobeNewswire","summary":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPLXlnYmZiWFptbXdIUE9mcE45Vzgzdjd4Qi02TzBJWGJzLVg5RzIwcGxUc3F4OHoxY19XOXg4U0FLbUdEMmZqYk5zcklwUEg4c1RqY3lLcWNVaDctZXNRNUtLeHVuRzlYdHZ4bDRMSWNIejRwVFpNUmJ4U1pfMi1jeUJEbzMzZ1F3R3prWk00SThVUnRFT3dxSnJEajROYkkwZ3JxWEw4SzNzb3RRdnFKMXJ5NzZUUUpBRzFocm1INm9ybUw2dWtfc0JMMFFRei1sV3Z6Zk81UEhmdk81?oc=5","date":"2023-07-10","type":"pipeline","source":"prnewswire.com","summary":"KRAS Inhibitors Market is Evolving Rapidly at a CAGR of 36% by 2032, Assesses DelveInsight - prnewswire.com","headline":"KRAS Inhibitors Market is Evolving Rapidly at a CAGR of 36% by 2032, Assesses DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxNZTEyWU5xQ3NFSHFoZTZyNHhrMHFUeDYwTlhxaDhXLXdWUWltTUJQS0ZwT3lzd3RXaW84amJIbUxQdFVGQWItdTFTck5tSUt6cXUyQUpEZXRkSUl2TU8wX3ZjOGd0b25kZHJucjVSSHhJczNkRUN6Ym9ELUlFX1poUkNrMjF6RVRFRnFmeTA0ZVhUaXVKLTlrUnkzMDhsZFZzcWFmZDNsNmd4clNGNUZaWDJHOUtGVkE3OEpybjhRckRqVjRWRm5aUmFHQzlvWWFsUERaUk1yMUYySEV5Yy1SY2V6bjctNEJoWm4zY1czNHJKNFF3V0t2WHV1TENtenJFY0pNaEplcTVEQlRhZC1NcHlHM3EtMnlZcWRfc2JSZTdPT2FIQUI3RDRMMDhlRWFkNUMyZmRVOEcxNVRaV0tR?oc=5","date":"2023-05-31","type":"trial","source":"prnewswire.com","summary":"CTLA-4 Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 40+ Leading Players Wheeling the Therapeutics Segment - prnewswire.com","headline":"CTLA-4 Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 40+ Lea","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}